Navigation Links
Vermillion Announces Receipt of NASDAQ Panel Decision

FREMONT, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced that it has received notification from The NASDAQ Stock Market LLC that the NASDAQ Listing Qualifications Panel has determined to delist the Company's securities from The NASDAQ Capital Market, effective as of the open of business on Thursday, September 25, 2008. The delisting is the result of the Company's noncompliance with the minimum stockholders' equity requirement for continued listing on The NASDAQ Capital Market, as set forth in Marketplace Rule 4310(c)(3).

The Company has been advised that its securities are immediately eligible for quotation in the Pink Sheets, an electronic quotation service for securities traded over-the-counter, effective as of the open of business on Thursday, September 25, 2008. The Company's shares will continue to trade under the symbol VRML. In addition, the Company has been advised that a Market Maker is filing the necessary application with the Financial Industry Regulatory Authority ("FINRA") to quote the securities and as a result we anticipate in the near future that the Company will be quoted on the Over-the-Counter Bulletin Board (the "OTCBB").

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at

About Pink Sheets LLC

Pink Sheets' centralized information network is a source of competitive market maker quotations, historical prices and corporate information about OTC issues and issuers. Pink Sheets is neither an SEC-Registered Stock Exchange nor a NASD Broker/Dealer. Investors must contact a NASD Broker/Dealer to trade in a security quoted on the Pink Sheets. More information is available at

About the OTCBB

The OTCBB is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in OTC equity securities. An OTC equity security generally is any equity that is not listed or traded on a national securities exchange. OTCBB securities include national, regional, and foreign equity issues, warrants, units, ADRs, and Direct Participation Programs. More information is available at

Forward Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions and the risks and uncertainties discussed in Vermillion's latest Form 10-K and Vermillion's periodic reports on Form 10-Q and Form 8-K. These forward-looking statements are based on Vermillion's current expectations. Vermillion is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. Forward-looking statements cannot be guaranteed and actual results may differ materially from Vermillion's current expectations. You are encouraged to read Vermillion's reports filed with the U.S. Securities and Exchange Commission, available at

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
2. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
3. Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
4. Vermillion Announces First Quarter 2008 Financial Results and Business Progress
5. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
6. Vermillion Announces Appointment of John Hamilton to Board of Directors
7. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
8. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Announces Effectiveness of Reverse Stock Split
11. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, a ... Emily Leproust, Ph.D., Twist Bioscience chief executive officer, ... Conference on December 1, 2015 at 3:10 p.m. ... York City. --> ... . Twist Bioscience is on Twitter. Sign up ...
(Date:11/24/2015)... , Nov. 24, 2015 Capricor Therapeutics, ... focused on the discovery, development and commercialization of first-in-class ... Chief Executive Officer, is scheduled to present at the ... at 10:50 a.m. EST, at The Lotte New York ... . . --> ...
(Date:11/24/2015)... NEW YORK , Nov. 24, 2015 According ... today than in 2005. This is something that many doctors, ... long time. One questions remains: with fewer PSA tests being ... cancer ? Dr. David Samadi, "Despite ... cancer, the disease remains the second leading cancer cause of ...
(Date:11/23/2015)... , ... November 23, 2015 , ... Noblis, Inc., a ... former Director, Plans and Programs, National Geospatial Intelligence Agency (NGA), has joined the Noblis ... an incredibly distinguished career in the intelligence community and the private sector,” said ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015  Vigilant Solutions announces today that Mr. ... of Directors. --> --> ... from the partnership at TPG Capital, one of the ... $140 Billion in revenue.  He founded and led TPG,s ... TPG companies, from 1997 to 2013.  In his first ...
(Date:11/12/2015)...   Growing need for low-cost, easy to ... paving the way for use of biochemical sensors ... in clinical, agricultural, environmental, food and defense applications. ... medical applications, however, their adoption is increasing in ... emphasis on improving product quality and growing need ...
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
Breaking Biology News(10 mins):